targeted protein degradation

NEW HAVEN, Conn. — September 28, 2026 Arvinas, Inc. announced that the first participant has been dosed in the...

PRINCETON, N.J. — September 26, 2026 Bristol Myers Squibb announced the first presentation of results from the pivotal Phase...

WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...

WILMINGTON, Del. — September 10, 2026 Prelude Therapeutics Incorporated announced that the U.S. Food and Drug Administration (FDA) has...

Watertown, Mass., September 3, 2026 C4 Therapeutics announced that new biomarker data evaluating the immunomodulatory effects of cemsidomide in...

WATERTOWN, Mass., Sept. 1, 2026 Kymera Therapeutics, Inc. has announced upcoming presentations featuring clinical data for KT-621, its first-in-class...

WALTHAM, Massachusetts, and HANGZHOU, China, August 13, 2026 Photys Therapeutics, Inc. and Polymed Biopharmaceuticals, Inc. announced the initiation of...

BRISBANE, Calif., Aug. 4, 2026 Nurix Therapeutics, Inc. announced the enrollment of the first patient in the registrational Phase...

NEW HAVEN, Conn., July 27, 2026 Biohaven Ltd. and Yale University have secured a significant legal victory after a...

Brisbane, California, USA | July 21, 2026 Nurix Therapeutics announced the official closing of its previously announced global collaboration...